Assembly Bio reports Q2 2026 results, expands ABI-6250 into cholestatic liver disease

Assembly Biosciences reported second quarter 2026 financial results on August 13, 2026 for the period ended June 30, 2026. The company announced expansion of ABI-6250 into cholestatic liver diseases, including PBC and PSC, with a Phase 2 study anticipated to initiate in the first quarter of 2027¹. It also completed a $115 million gross financing expected to extend funding beyond planned ABI-6250 Phase 2 studies in hepatitis delta virus (HDV) and cholestatic liver diseases¹.

On the Gilead collaboration, Assembly Bio received the clinical development plan from Gilead Sciences for the herpes simplex virus (HSV) helicase-primase inhibitor program, indicating GS-1179 (formerly ABI-1179) has been selected to advance, with a Phase 2 clinical trial in participants with recurrent genital herpes expected to initiate by the end of 2026¹. The program is also being considered for possible evaluation as part of a combination strategy with HIV pre-exposure prophylaxis (PrEP)¹. Assembly Bio's decision to opt in to the 40% U.S. cost-profit share will be made after receipt and review of Gilead's commercial cost estimates, which will complete the opt-in package¹.

Financially, cash, cash equivalents and marketable securities were $320.4 million as of June 30, 2026, compared to $226.6 million as of March 31, 2026¹. The company's cash position, including the first $75 million extension fee due from Gilead in the fourth quarter of 2026 following the third anniversary of the collaboration agreement, is projected to fund operations into 2029¹.

Collaboration revenue was $13.4 million for the three months ended June 30, 2026, compared to $9.6 million for the same period in 2025¹. R&D expenses were $14.9 million compared to $16.1 million a year earlier¹, and net loss was $3.9 million, or $0.20 per basic and diluted share, compared to $10.2 million, or $1.33 per share, in the prior-year quarter¹.